Pennvax-G: Interim Phase I data

Interim data from 11 healthy volunteers in a U.S. cohort of the open-label Phase I RV262 trial showed that Inovio's Pennvax-G vaccine boosted with the modified vaccinia Ankara-Chiang Mai Double Recombinant (MVA-CMDR) virus vector vaccine produced anti-env CD4+ and CD8+ T cell responses in 100% and 45% of subjects, respectively, after the first MVA-CDMR boost. After the second MVA-CDMR boost, CD4+ and CD8+ T cell responses were observed in 73% and 45% of subjects, respectively. Data were presented at the AIDS Vaccine meeting in Bangkok. ...